SCHEMBL7516256

SCHEMBL7516256

Cc1cc(C=O)c(C)nc1-c1nc2cc(Cl)c(Cl)cc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
AMY1A P0DUB6 2/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
NPBWR1 P48145 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
LMNA P02545 1/20 0.37
GRIK1 P39086 1/20 0.37
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7511462 0.78 IGF1R (0.46) MEN1KMT2ANPC1RAB9AGAA
SCHEMBL7511467 0.78 IGF1R (0.46) MEN1KMT2ANPC1RAB9AGAA
SCHEMBL7518468 0.70 RHEB (0.54) RHEBMEN1KMT2ANPC1RAB9A
SCHEMBL7515773 0.70 NPC1 (0.56) RHEBMEN1KMT2ANPC1RAB9A
SCHEMBL5752586 0.69 ALDH1A1 (0.53) MEN1KMT2ANPC1RAB9AGAA
SCHEMBL29954905 0.69 ALDH1A1 (0.53) MEN1KMT2ANPC1RAB9AGAA
SCHEMBL5752591 0.69 ALDH1A1 (0.53) MEN1KMT2ANPC1RAB9AGAA
SCHEMBL7512341 0.69 RHEB (0.63) RHEBMEN1KMT2ANPC1RAB9A
SCHEMBL23782199 0.68 GAA (0.49) RHEBMEN1KMT2ANPC1RAB9A
SCHEMBL2336514 0.68 PTGES (0.45) CYP2D6AMY1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 RHEB 1710/4885MEN1 2033/4885KMT2A 1503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.